- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01433627
Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX (MATRIX)
Phase IIIb Study Minimizing Adverse Haemmhorragic Events by TRansradial Access Site and Systemic Implementation of angioX (MATRIX)
Study Overview
Status
Conditions
Intervention / Treatment
- Other: trans-radial and short-term bivalirudin
- Other: trans-radial and long-term bivalirudin infusion
- Other: trans-radial and standard of care pharmacology
- Other: Trans-femoral and Short-term bivalirudin
- Other: trans-femoral and long-term bivalirudin infusion
- Other: trans-femoral and standard of care pharmacology
Detailed Description
The use of combined antithrombotic therapies over the last two decades has decreased the risk of a heart attack after percutaneous coronary intervention substantially but has also been associated with a significant increase in bleeding risk. Therapies or strategies that maintain the benefits seen with currently available antithrombotic therapies but which have lower bleeding risk are therefore of great clinical importance. Indeed, major bleeding is currently the most common non-cardiac complication of therapy for patients with coronary artery disease who have undergone percutaneous coronary intervention (PCI).
Bleeding in patients with acute coronary syndrome (ACS) is associated with an increased risk of long term mortality and morbidity, and this relationship is currently thought to be causal. Therefore' reducing the frequency of bleeding events while maintaining efficacy is an important goal in the management of patients with ACS. The most common site of bleeding in invasively managed patients with ACS is at the femoral artery puncture site used for heart catheterization
The MATRIX study is a multi-centre, prospective, randomised, open-label, 2 by 2 factorial comparison of trans-radial vs. trans-femoral intervention and bivalirudin vs. unfractionated heparin and provisional use of glycoprotein IIb/IIIa inhibitor.
Objectives:
- To demonstrate that trans-radial intervention as compared to femoral access site is associated to lower rate of the composite endpoint of death, MI or stroke within the first 30 days after randomization in acute coronary syndrome patients undergoing early invasive management.
- To demonstrate that bivalirudin infusion as compared to standard of care therapy consisting of unfractionated heparin and provisional use of glycoprotein IIb/IIIa inhibitors are associated to lower rate of the composite endpoint of death, MI or stroke within the first 30 days after randomization in acute coronary syndrome patients undergoing early invasive management.
Patients randomly assigned to receive bivalirudin will be randomized to stop bivalirudin infusion at the end of PCI or to prolong bivalirudin at an infusion rate of 0.25 mg/kg/hour for at least 6 hours after completion of PCI. The primary hypothesis in this sub-randomization is that prolonged post-intervention bivalirudin infusion will be superior to no bivalirudin post-PCI infusion with respect to the net composite outcome consisting of any death, MI, stroke, urgent TVR, stent thrombosis and BARC-defined type 3 and 5 bleeding events within 30 days. Secondary objectives for the sub-randomization of prolonged bivalirudin versus no post-PCI infusion in the bivalirudin group will consist of each component of the primary composite endpoint through the entire follow-up duration
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Rome, Italy
- Università Campus Bio-Medico di Roma
-
-
Abruzzo
-
Chieti, Abruzzo, Italy
- Ospedale Clinicizzato SS Annunziata di Chieti
-
Pescara, Abruzzo, Italy
- Ospedale Civile Santo Spirito
-
-
Calabria
-
Catanzaro, Calabria, Italy
- Azienda Ospedaliera Pugliese Ciaccio - Catanzaro
-
-
Campania
-
Napoli, Campania, Italy
- A.O. AORN Cardarelli
-
Napoli, Campania, Italy
- Azienda Ospedaliera Monaldi
-
Napoli, Campania, Italy
- Policlinico Federico II
-
-
Emilia Romagna
-
Bologna, Emilia Romagna, Italy
- Policlinico Sant'Orsola Malpighi
-
Ferrara, Emilia Romagna, Italy, 44100
- University Hospital of Ferrara
-
Forlì, Emilia Romagna, Italy
- Ospedale G. B. Morgagni
-
Reggio Emilia, Emilia Romagna, Italy
- Azienda S. Maria Nuova di Reggio Emilia
-
Rimini, Emilia Romagna, Italy
- Ospedale Degli Infermi
-
-
Friuli Venezia Giulia
-
Trieste, Friuli Venezia Giulia, Italy
- Azienda Ospedaliera Universitaria Ospedali Riuniti
-
Udine, Friuli Venezia Giulia, Italy
- Azienda Ospedaliera S. Maria della Misericordia di Udine
-
-
Lazio
-
Latina, Lazio, Italy
- Ospedale Santa Maria Goretti
-
Roma, Lazio, Italy
- A.O. Sandro Pertini
-
Roma, Lazio, Italy
- Ospedale del Santo Spirito in Sassia
-
Roma, Lazio, Italy
- Ospedale San Camillo di Roma
-
Roma, Lazio, Italy
- Policlinico Casilino
-
-
Liguria
-
Genova, Liguria, Italy
- Azienda Ospedaliera Universitaria "San Martino"
-
Genova, Liguria, Italy
- Ospedale Villa Scassi
-
-
Lombardia
-
Brescia, Lombardia, Italy
- Spedali Civili di Brescia
-
Como, Lombardia, Italy
- Azienda Ospedaliera Sant'Anna di Como
-
Desio, Lombardia, Italy
- Azienda Ospedaliera di Desio e Vimercate - P.O. di Desio
-
Erba, Lombardia, Italy
- Ospedale Sacra Famiglia
-
Lodi, Lombardia, Italy
- Ospedale di Lodi
-
Milano, Lombardia, Italy
- A.O: Fatebenefratelli e oftalmico
-
Sesto San Giovanni, Lombardia, Italy
- IRCCS Multimedica
-
Treviglio, Lombardia, Italy
- A.O. Treviglio
-
Vimercate, Lombardia, Italy
- A. O. Ospedale Civile di Vimercate
-
Zingonia, Lombardia, Italy
- Policlinico San Marco
-
-
MI
-
Rozzano, MI, Italy
- Istituto Clinico Humanitas IRCCS
-
-
Marche
-
Ascoli Piceno, Marche, Italy
- A.O. G. Mazzoni
-
Pesaro, Marche, Italy
- Azienda Ospedaliera San Salvatore
-
-
Piemonte
-
Cuneo, Piemonte, Italy
- Ospedale S. Croce e Carlo
-
Novara, Piemonte, Italy
- Azienda Ospedaliero-Universitaria "Maggiore della Carità"
-
Orbassano, Piemonte, Italy
- A. O. Universitaria San Luigi Gonzaga di Orbassano
-
Savigliano, Piemonte, Italy
- Ospedali Riuniti ASL 17
-
Torino, Piemonte, Italy
- A.O. Universitaria Molinette San Giovanni Battista
-
Torino, Piemonte, Italy
- Ospedale San Giovanni Bosco
-
-
Puglia
-
Bari, Puglia, Italy
- Ospedale Di Venere - ASL Bari
-
Lecce, Puglia, Italy
- Città di Lecce Ospedale (GVM)
-
Lecce, Puglia, Italy
- Ospedale Vito Fazzi
-
San Giovanni Rotondo, Puglia, Italy
- IRCCS Ospedale Casa Sollievo della Sofferenza
-
Taranto, Puglia, Italy
- Casa di cura Villa Verde
-
-
RA
-
Cotignola, RA, Italy
- Maria Cecilia Hospital
-
-
Sardegna
-
Carbonia, Sardegna, Italy
- Azienda USL Sirai
-
Nuoro, Sardegna, Italy
- Ospedale San Francesco
-
-
Sicilia
-
Catania, Sicilia, Italy
- A. O. Universitaria Policlinico V. Emanuele Ferrarotto
-
Palermo, Sicilia, Italy
- Villa Maria Eleonora Hospital
-
Siracusa, Sicilia, Italy
- Ospedale Umberto I di Siracusa
-
Taormina, Sicilia, Italy
- Ospedale S. Vincenzo
-
-
Sicily
-
Sciacca, Sicily, Italy
- A.O. Civili Riuniti - Giovanni Paolo II
-
-
TO
-
Rivoli, TO, Italy
- Ospedale Degli Infermi
-
-
Toscana
-
Arezzo, Toscana, Italy
- P.O. Zona Aretina-Ospedale San Donato
-
Grosseto, Toscana, Italy
- Azienda USL - Grosseto
-
Massa Carrara, Toscana, Italy
- Ospedale del Cuore "G. Pasquinucci" Massa
-
Pisa, Toscana, Italy
- Azienda Ospedaliera Universitaria Pisana
-
-
Trentino Alto Adige
-
Trento, Trentino Alto Adige, Italy
- Presidio Ospedaliero Santa Chiara
-
-
Veneto
-
Este, Veneto, Italy
- Presidio Ospedaliero di Este
-
Legnago, Veneto, Italy
- Ospedale Mater Salutis di Legnago
-
Mirano, Veneto, Italy
- Ospedale Civile di Mirano
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
NSTEACS definition: Patients with all of the following criteria will be eligible:
- history consistent with new, or worsening ischemia, occurring at rest or with minimal activity;
- enrollment within 7 days of the most recent symptoms;
- planned coronary angiography with possible indication to PCI;
- at least 2 of the following criteria: 1. Aged 60 years or older, 2. Troponin T or I or creatine kinase MB above the upper limit of normal; 3. Electrocardiograph changes compatible with ischemia, ie, ST depression of 1 mm or greater in 2 contiguous leads, T-wave inversion more than 3 mm, or any dynamic ST shifts;
STEMI definition: i) chest pain for >20 min with an electrocardiographic ST-segment elevation ≥1 mm in two or more contiguous electrocardiogram (ECG) leads, or with a new left bundle-branch block, or an infero-lateral myocardial infarction (MI) with ST segment depression of ≥1 mm in ≥2 of leads V1-3 with a positive terminal T wave and ii) admission either within 12 h of symptom onset or between 12 and 24 h after onset with evidence of continuing ischemia or previous lytic treatment.
Exclusion Criteria:
- Patients who can not give informed consent or have a life expectancy of <30 days
- Allergy/intolerance to Bivalirudin or unfractionated heparin.
- Stable or silent CAD as indication to coronary angiography
- Treatment with LWMH within the past 6 hours
- Treatment with any GPI in the previous 3 days
- Absolute contraindications or allergy that cannot be pre-medicated to iodinated contrast or to any of the study medications including aspirin or clopidogrel.
- Contraindications to angiography, including but not limited to severe peripheral vascular disease.
- If it is known pregnant or nursing mothers. Women of child-bearing age will be asked if they are pregnant or think that they may be pregnant.
- If it is known a creatinine clearance <30 mL/min or dialysis dependent.
- Previous enrollment in this study.
- Treatment with other investigational drugs or devices within the 30 days preceding
- Randomisation or planned use of other investigational drugs or devices in this trial.
- Severe uncontrolled hypertension (defined as persistent systolic blood pressure higher than 220 mmHg despite medical treatment).
- Subacute bacterial endocarditis
- PCI in the previous 30 days
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: trans-radial and short-term Bivalirudin
Patients will be randomized to receive a trans-radial intervention and concomitant bivalirudin infusion.
bivalirudin will be stopped at the end of PCI.
|
trans-radial intervention followed by Bivalirudin given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h.
This infusion should be run continuously until completion of PCI at which time the infusion should be stopped.
Other Names:
|
Experimental: trans-radial and long-term bivalirudin
Trans-radial intervention: will be performed according to institutional guidelines and established local practice. Bivalirudin: given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be reduced to a dose of 0.25 mg/kg/h for at least 6 hours. An optional higher-dose infusion of 1.75 mg/kg/h is also permitted for up to 4 hours in the prolonged infusion arm but prohibited in the short bivalirudin group. |
Trans-radial intervention: will be performed according to institutional guidelines and established local practice. Bivalirudin: given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be reduced to a dose of 0.25 mg/kg/h for at least 6 hours. An optional higher-dose infusion of 1.75 mg/kg/h is also permitted for up to 4 hours in the prolonged infusion arm but prohibited in the short bivalirudin group.
Other Names:
|
Experimental: trans-radial and standard of care pharmacology
Trans-radial intervention: will be performed according to institutional guidelines and established local practice. unfractionated heparin (UFH) which may be followed by the addition of a glycoprotein IIb/IIIa inhibitor |
Unfractionated heparin (UFH) (100 IU/kg with no glycoprotein IIb/IIIa inhibitor (GPI) and 60 IU/kg with a GPI); +/- routine or bail out eptifibatide (two 180 μg /kg boluses with a 10 minute interval followed by an infusion of 2.0 μg /kg/min for 72-96 hours) or tirofiban (25 μg/kg followed by an infusion of 0.15 μg/kg/min for 18 to 24 hours) or abciximab (bolus of 0.25 mg/kg followed by an infusion of 0.125 μg/kg/min for 12-24 hours (maximum dose, 10 μg/min).
Other Names:
|
Experimental: trans-femoral and short-term bivalirudin
Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice. Bivalirudin will be given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI. |
Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice. Bivalirudin will be given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI.
Other Names:
|
Experimental: Trans-femoral and long-term bivalirudin
Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice. Bivalirudin will be given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be reduced to a dose of 0.25 mg/kg/h for at least 6 hours. An optional higher-dose infusion of 1.75 mg/kg/h is also permitted for up to 4 hours in the prolonged infusion arm but prohibited in the short bivalirudin group. |
Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice. Bivalirudin will be given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be reduced to a dose of 0.25 mg/kg/h for at least 6 hours. An optional higher-dose infusion of 1.75 mg/kg/h is also permitted for up to 4 hours in the prolonged infusion arm but prohibited in the short bivalirudin group.
Other Names:
|
Active Comparator: trans-femoral and standard of care pharmacology
Trans-femoral intervention: will be performed according to institutional guidelines and established local practice.
Access closure devices are allowed as per local practice.
Unfractionated heparin (UFH) (100 IU/kg with no glycoprotein IIb/IIIa inhibitor (GPI) and 60 IU/kg with a GPI); +/- routine or bail out eptifibatide (two 180 μg /kg boluses with a 10 minute interval followed by an infusion of 2.0 μg /kg/min for 72-96 hours) or tirofiban (25 μg/kg followed by an infusion of 0.15 μg/kg/min for 18 to 24 hours) or abciximab (bolus of 0.25 mg/kg followed by an infusion of 0.125 μg/kg/min for 12-24 hours (maximum dose, 10 μg/min).
|
Trans-femoral intervention: will be performed according to institutional guidelines and established local practice.
Access closure devices are allowed as per local practice.
Unfractionated heparin (UFH) (100 IU/kg with no glycoprotein IIb/IIIa inhibitor (GPI) and 60 IU/kg with a GPI); +/- routine or bail out eptifibatide (two 180 μg /kg boluses with a 10 minute interval followed by an infusion of 2.0 μg /kg/min for 72-96 hours) or tirofiban (25 μg/kg followed by an infusion of 0.15 μg/kg/min for 18 to 24 hours) or abciximab (bolus of 0.25 mg/kg followed by an infusion of 0.125 μg/kg/min for 12-24 hours (maximum dose, 10 μg/min).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the composite of Death, non-fatal myocardial infarction or stroke
Time Frame: 30 days
|
To demonstrate in ACS patients undergoing an early invasive management, i.e. diagnostic coronary angiogram+PCI or ad hoc planned PCI that trans-radial intervention as compared to femoral access site is associated to lower rate of the composite endpoint of death, MI or stroke within the first 30 days after randomization.
|
30 days
|
The composite of death, non-fatal myocardial infarction or stroke
Time Frame: 30 days
|
To demonstrate that in an ACS patients with an intended PCI treatment strategy or in whom upstream treatment was felt necessary by local investigators the use of bivalirudin as compared to unfractionated heparin (UFH) plus or minus Glycoprotein IIb/IIIa inhibitor (GPI) is associated to lower rate of the composite endpoint of death, MI or stroke within the first 30 days after randomization.
|
30 days
|
Death, non-fatal myocardial infarction, stroke, stent thrombosis or BARC-defined type 3 or 5 bleedings
Time Frame: 30 days
|
The primary hypothesis of this sub-randomization is that prolonged post-intervention bivalirudin infusion (long bivalirudin arm) will be superior to peri-PCI bivalirudin infusion only (short bivalirudin arm) with respect to the net composite outcomes consisting of any death, MI, stroke, stent thrombosis or BARC-defined type 3 and 5 bleeding events within 30 days.
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the composite endpoint of death, MI, stroke or BARC-defined type 3 and 5 major bleeding complications
Time Frame: 30 days
|
Key secondary objective: To demonstrate that trans-radial intervention as compared to femoral access site is associated to lower rate of the composite endpoint of death, MI, stroke or BARC-defined type 3 and 5 major bleeding complications within the first 30 days after randomization.
|
30 days
|
Death, non-fatal MI, stroke or BARC-defined type 3 and 5 major bleeding
Time Frame: 30 days
|
To demonstrate that use of bivalirudin as compared to unfractionated heparin (UFH) plus or minus Glycoprotein IIb/IIIa inhibitor (GPI) is associated to lower rate of the composite endpoint of death, MI, stroke or BARC-defined type 3 and 5 major bleeding complications within the first 30 days after randomization.
|
30 days
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Marco Valgimigli, MD PhD, Erasmus MC, Thoraxcenter, The Netherlands
Publications and helpful links
General Publications
- Dan K, Garcia-Garcia HM, Yacob O, Kuku KO, Diaz-Torres MA, Picchi A, Sardella G, Adamo M, Frigoli E, Limbruno U, Rigattieri S, Diletti R, Boccuzzi G, Zimarino M, Contarini M, Russo F, Calabro P, Ando G, Varbella F, Garducci S, Palmieri C, Briguori C, Karagiannis A, Dijkstra J, Valgimigli M. Ultra-Short Term Evaluation of Coronary Vessel Wall Changes in Reference Segments Adjacent to Culprit Lesions in ST-Segment Elevation Myocardial Infarction. J Invasive Cardiol. 2021 Dec;33(12):E923-E930. Epub 2021 Nov 18.
- Landi A, Branca M, Ando G, Russo F, Frigoli E, Gargiulo G, Briguori C, Vranckx P, Leonardi S, Gragnano F, Calabro P, Campo G, Ambrosio G, Santucci A, Varbella F, Zaro T, Heg D, Windecker S, Juni P, Pedrazzini G, Valgimigli M; MATRIX Investigators. Acute kidney injury in patients with acute coronary syndrome undergoing invasive management treated with bivalirudin vs. unfractionated heparin: insights from the MATRIX trial. Eur Heart J Acute Cardiovasc Care. 2021 Dec 18;10(10):1170-1179. doi: 10.1093/ehjacc/zuab080.
- Gragnano F, Branca M, Frigoli E, Leonardi S, Vranckx P, Di Maio D, Monda E, Fimiani L, Fioretti V, Chianese S, Esposito F, Franzese M, Scalise M, D'Angelo C, Scalise R, De Blasi G, Ando G, Esposito G, Calabro P, Windecker S, Pedrazzini G, Valgimigli M; MATRIX Trial Investigators. Access-Site Crossover in Patients With Acute Coronary Syndrome Undergoing Invasive Management. JACC Cardiovasc Interv. 2021 Feb 22;14(4):361-373. doi: 10.1016/j.jcin.2020.11.042.
- Leonardi S, Gragnano F, Carrara G, Gargiulo G, Frigoli E, Vranckx P, Di Maio D, Spedicato V, Monda E, Fimiani L, Fioretti V, Esposito F, Avvedimento M, Magliulo F, Leone A, Chianese S, Franzese M, Scalise M, Schiavo A, Mazzone P, Esposito G, Andò G, Calabrò P, Windecker S, Valgimigli M. Prognostic Implications of Declining Hemoglobin Content in Patients Hospitalized With Acute Coronary Syndromes. J Am Coll Cardiol. 2021 Feb 2;77(4):375-388. doi: 10.1016/j.jacc.2020.11.046.
- Gargiulo G, Valgimigli M, Sunnaker M, Vranckx P, Frigoli E, Leonardi S, Spirito A, Gragnano F, Manavifar N, Galea R, De Caterina AR, Calabro P, Esposito G, Windecker S, Hunziker L. Choice of access site and type of anticoagulant in acute coronary syndromes with advanced Killip class or out-of-hospital cardiac arrest. Rev Esp Cardiol (Engl Ed). 2020 Nov;73(11):893-901. doi: 10.1016/j.rec.2020.01.005. Epub 2020 Mar 6. English, Spanish.
- Garcia-Garcia HM, Picchi A, Sardella G, Adamo M, Frigoli E, Limbruno U, Rigattieri S, Diletti R, Boccuzzi G, Zimarino M, Contarini M, Russo F, Calabro' P, Ando G, Varbella F, Garducci S, Palmieri C, Briguori C, Kuku KO, Rothenbuhler M, Karagiannis A, Valgimigli M. Comparison of intra-procedural vs. post-stenting prolonged bivalirudin infusion for residual thrombus burden in patients with ST-segment elevation myocardial infarction undergoing: the MATRIX (Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and angioX) OCT study. Eur Heart J Cardiovasc Imaging. 2019 Dec 1;20(12):1418-1428. doi: 10.1093/ehjci/jez040.
- Gargiulo G, Carrara G, Frigoli E, Leonardi S, Vranckx P, Campo G, Varbella F, Calabro P, Zaro T, Bartolini D, Briguori C, Ando G, Ferrario M, Limbruno U, Colangelo S, Sganzerla P, Russo F, Nazzaro MS, Esposito G, Ferrante G, Santarelli A, Sardella G, Windecker S, Valgimigli M. Post-Procedural Bivalirudin Infusion at Full or Low Regimen in Patients With Acute Coronary Syndrome. J Am Coll Cardiol. 2019 Feb 26;73(7):758-774. doi: 10.1016/j.jacc.2018.12.023.
- Valgimigli M, Frigoli E, Leonardi S, Vranckx P, Rothenbuhler M, Tebaldi M, Varbella F, Calabro P, Garducci S, Rubartelli P, Briguori C, Ando G, Ferrario M, Limbruno U, Garbo R, Sganzerla P, Russo F, Nazzaro M, Lupi A, Cortese B, Ausiello A, Ierna S, Esposito G, Ferrante G, Santarelli A, Sardella G, de Cesare N, Tosi P, van 't Hof A, Omerovic E, Brugaletta S, Windecker S, Heg D, Juni P; MATRIX Investigators. Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. Lancet. 2018 Sep 8;392(10150):835-848. doi: 10.1016/S0140-6736(18)31714-8. Epub 2018 Aug 25.
- Gargiulo G, Carrara G, Frigoli E, Vranckx P, Leonardi S, Ciociano N, Campo G, Varbella F, Calabro P, Garducci S, Iannone A, Briguori C, Ando G, Crimi G, Limbruno U, Garbo R, Sganzerla P, Russo F, Lupi A, Cortese B, Ausiello A, Ierna S, Esposito G, Zavalloni D, Santarelli A, Sardella G, Tresoldi S, de Cesare N, Sciahbasi A, Zingarelli A, Tosi P, van 't Hof A, Omerovic E, Brugaletta S, Windecker S, Valgimigli M. Bivalirudin or Heparin in Patients Undergoing Invasive Management of Acute Coronary Syndromes. J Am Coll Cardiol. 2018 Mar 20;71(11):1231-1242. doi: 10.1016/j.jacc.2018.01.033.
- Gargiulo G, Ariotti S, Vranckx P, Leonardi S, Frigoli E, Ciociano N, Tumscitz C, Tomassini F, Calabro P, Garducci S, Crimi G, Ando G, Ferrario M, Limbruno U, Cortese B, Sganzerla P, Lupi A, Russo F, Garbo R, Ausiello A, Zavalloni D, Sardella G, Esposito G, Santarelli A, Tresoldi S, Nazzaro MS, Zingarelli A, Petronio AS, Windecker S, da Costa BR, Valgimigli M. Impact of Sex on Comparative Outcomes of Radial Versus Femoral Access in Patients With Acute Coronary Syndromes Undergoing Invasive Management: Data From the Randomized MATRIX-Access Trial. JACC Cardiovasc Interv. 2018 Jan 8;11(1):36-50. doi: 10.1016/j.jcin.2017.09.014.
- Ando G, Cortese B, Russo F, Rothenbuhler M, Frigoli E, Gargiulo G, Briguori C, Vranckx P, Leonardi S, Guiducci V, Belloni F, Ferrari F, de la Torre Hernandez JM, Curello S, Liistro F, Perkan A, De Servi S, Casu G, Dellavalle A, Fischetti D, Micari A, Loi B, Mangiacapra F, Russo N, Tarantino F, Saia F, Heg D, Windecker S, Juni P, Valgimigli M; MATRIX Investigators. Acute Kidney Injury After Radial or Femoral Access for Invasive Acute Coronary Syndrome Management: AKI-MATRIX. J Am Coll Cardiol. 2017 May 11:S0735-1097(17)36897-3. doi: 10.1016/j.jacc.2017.02.070. Online ahead of print.
- Leonardi S, Frigoli E, Rothenbuhler M, Navarese E, Calabro P, Bellotti P, Briguori C, Ferlini M, Cortese B, Lupi A, Lerna S, Zavallonito-Parenti D, Esposito G, Tresoldi S, Zingarelli A, Rigattieri S, Palmieri C, Liso A, Abate F, Zimarino M, Comeglio M, Gabrielli G, Chieffo A, Brugaletta S, Mauro C, Van Mieghem NM, Heg D, Juni P, Windecker S, Valgimigli M; MATRIX Investigators. Bivalirudin or unfractionated heparin in patients with acute coronary syndromes managed invasively with and without ST elevation (MATRIX): randomised controlled trial. BMJ. 2016 Sep 27;354:i4935. doi: 10.1136/bmj.i4935.
- Valgimigli M, Frigoli E, Leonardi S, Rothenbuhler M, Gagnor A, Calabro P, Garducci S, Rubartelli P, Briguori C, Ando G, Repetto A, Limbruno U, Garbo R, Sganzerla P, Russo F, Lupi A, Cortese B, Ausiello A, Ierna S, Esposito G, Presbitero P, Santarelli A, Sardella G, Varbella F, Tresoldi S, de Cesare N, Rigattieri S, Zingarelli A, Tosi P, van 't Hof A, Boccuzzi G, Omerovic E, Sabate M, Heg D, Juni P, Vranckx P; MATRIX Investigators. Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. N Engl J Med. 2015 Sep 10;373(11):997-1009. doi: 10.1056/NEJMoa1507854. Epub 2015 Sep 1.
- Ando G, Cortese B, Frigoli E, Gagnor A, Garducci S, Briguori C, Rubartelli P, Calabro P, Valgimigli M; MATRIX investigators. Acute kidney injury after percutaneous coronary intervention: Rationale of the AKI-MATRIX (acute kidney injury-minimizing adverse hemorrhagic events by TRansradial access site and systemic implementation of angioX) sub-study. Catheter Cardiovasc Interv. 2015 Nov;86(5):950-7. doi: 10.1002/ccd.25932. Epub 2015 Apr 9. Erratum In: Catheter Cardiovasc Interv. 2016 Dec;88(7):1188.
- Valgimigli M, Gagnor A, Calabro P, Frigoli E, Leonardi S, Zaro T, Rubartelli P, Briguori C, Ando G, Repetto A, Limbruno U, Cortese B, Sganzerla P, Lupi A, Galli M, Colangelo S, Ierna S, Ausiello A, Presbitero P, Sardella G, Varbella F, Esposito G, Santarelli A, Tresoldi S, Nazzaro M, Zingarelli A, de Cesare N, Rigattieri S, Tosi P, Palmieri C, Brugaletta S, Rao SV, Heg D, Rothenbuhler M, Vranckx P, Juni P; MATRIX Investigators. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. Lancet. 2015 Jun 20;385(9986):2465-76. doi: 10.1016/S0140-6736(15)60292-6. Epub 2015 Mar 16.
- Valgimigli M; MATRIX investigators. Design and rationale for the Minimizing Adverse haemorrhagic events by TRansradial access site and systemic Implementation of angioX program. Am Heart J. 2014 Dec;168(6):838-45.e6. doi: 10.1016/j.ahj.2014.08.013. Epub 2014 Sep 16.
- Sciahbasi A, Calabro P, Sarandrea A, Rigattieri S, Tomassini F, Sardella G, Zavalloni D, Cortese B, Limbruno U, Tebaldi M, Gagnor A, Rubartelli P, Zingarelli A, Valgimigli M. Randomized comparison of operator radiation exposure comparing transradial and transfemoral approach for percutaneous coronary procedures: rationale and design of the minimizing adverse haemorrhagic events by TRansradial access site and systemic implementation of angioX - RAdiation Dose study (RAD-MATRIX). Cardiovasc Revasc Med. 2014 Jun;15(4):209-13. doi: 10.1016/j.carrev.2014.03.010. Epub 2014 Mar 26.
- Valgimigli M, Calabro P, Cortese B, Frigoli E, Garducci S, Rubartelli P, Ando G, Santarelli A, Galli M, Garbo R, Repetto A, Ierna S, Briguori C, Limbruno U, Violini R, Gagnor A; MATRIX investigators. Scientific foundation and possible implications for practice of the Minimizing Adverse Haemorrhagic Events by Transradial Access Site andSystemic Implementation of AngioX (MATRIX) trial. J Cardiovasc Transl Res. 2014 Feb;7(1):101-11. doi: 10.1007/s12265-013-9537-1. Epub 2014 Jan 7.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Acute Coronary Syndrome
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Protease Inhibitors
- Antithrombins
- Serine Proteinase Inhibitors
- Anticoagulants
- Bivalirudin
- Hirudins
Other Study ID Numbers
- RFBU 11-I
- 2011-000430-11 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on STEMI
-
Clinical Operations WCN B.V.SanofiEnrolling by invitationAtherosclerotic Cardiovascular Disease | STEMI | Non STEMINetherlands
-
Kingston UniversityUniversity of Leeds; Swansea University; London Ambulance Service; West Midlands... and other collaboratorsCompletedAcute Coronary Syndrome | STEMI | Non STEMIUnited Kingdom
-
Karolinska InstitutetEnrolling by invitation
-
Beijing Friendship HospitalActive, not recruiting
-
University of OradeaCompleted
-
Prolocor, IncRecruitingSTEMI | NSTEMIUnited States
-
Assistance Publique - Hôpitaux de ParisCompletedPrimary PCI - STEMIFrance
-
VesalioRecruitingSegment Elevation Myocardial Infarction (STEMI)Switzerland
-
University of PisaCompleted
-
AstraZenecaCompletedMyocardial Infarction | Segment Elevation Myocardial Infarction (STEMI)Australia, France, Italy, Spain, United Kingdom, Sweden, Germany, Hungary, Denmark, Austria, Canada, Netherlands, Algeria
Clinical Trials on trans-radial and short-term bivalirudin
-
Hospices Civils de LyonCompleted
-
Thomas Jefferson UniversityNational Cancer Institute (NCI)SuspendedAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Invasive Breast Carcinoma | Hormone Receptor Positive Breast Carcinoma | Breast Ductal Carcinoma in Situ | HER2 Negative Breast CarcinomaUnited States
-
University of AlbertaCanadian Institutes of Health Research (CIHR); Canadian Cancer Society (CCS)Active, not recruiting
-
Peking University Sixth HospitalCompleted
-
Biobeat Technologies Ltd.CompletedCongestive Heart FailureIsrael
-
West China HospitalTerminated
-
University Hospitals of North Midlands NHS TrustNot yet recruiting
-
AdventHealthHalyard HealthCompletedPain, Postoperative | Anesthesia, LocalUnited States
-
Tang-Du HospitalActive, not recruiting
-
Derming SRLCompleted